macrogenics inc. - MGNX
MGNX
Close Chg Chg %
1.78 -0.03 -1.92%
Open Market
1.75
-0.03 (1.92%)
Volume: 200.07K
Last Updated:
Jan 15, 2026, 11:02 AM EDT
Company Overview: macrogenics inc. - MGNX
MGNX Key Data
| Open $1.78 | Day Range 1.72 - 1.78 |
| 52 Week Range 0.99 - 3.37 | Market Cap $112.60M |
| Shares Outstanding 63.26M | Public Float 58.15M |
| Beta 1.52 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.21 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.64M |
MGNX Performance
| 1 Week | -2.73% | ||
| 1 Month | 18.67% | ||
| 3 Months | 7.88% | ||
| 1 Year | -40.67% | ||
| 5 Years | -91.36% |
MGNX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
7
Full Ratings ➔
About macrogenics inc. - MGNX
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
MGNX At a Glance
MacroGenics, Inc.
9704 Medical Center Drive
Rockville, Maryland 20850-3368
| Phone | 1-301-251-5172 | Revenue | 149.96M | |
| Industry | Pharmaceuticals: Major | Net Income | -66,966,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 155.259% | |
| Fiscal Year-end | 12 / 2025 | Employees | 341 | |
| View SEC Filings |
MGNX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.357 |
| Price to Book Ratio | 1.759 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.382 |
| Enterprise Value to Sales | 0.262 |
| Total Debt to Enterprise Value | 0.953 |
MGNX Efficiency
| Revenue/Employee | 439,771.261 |
| Income Per Employee | -196,381.232 |
| Receivables Turnover | 34.802 |
| Total Asset Turnover | 0.519 |
MGNX Liquidity
| Current Ratio | 3.917 |
| Quick Ratio | 3.917 |
| Cash Ratio | 3.632 |
MGNX Profitability
| Gross Margin | 86.771 |
| Operating Margin | -73.737 |
| Pretax Margin | -44.026 |
| Net Margin | -44.655 |
| Return on Assets | -23.197 |
| Return on Equity | -49.85 |
| Return on Total Capital | -43.621 |
| Return on Invested Capital | -40.406 |
MGNX Capital Structure
| Total Debt to Total Equity | 32.278 |
| Total Debt to Total Capital | 24.402 |
| Total Debt to Total Assets | 13.846 |
| Long-Term Debt to Equity | 28.087 |
| Long-Term Debt to Total Capital | 21.233 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Macrogenics Inc. - MGNX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 77.45M | 151.94M | 58.75M | 149.96M | |
Sales Growth
| -26.16% | +96.19% | -61.33% | +155.26% | |
Cost of Goods Sold (COGS) incl D&A
| 13.91M | 19.25M | 17.87M | 19.84M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 11.26M | 11.87M | 9.64M | 7.54M | |
Depreciation
| 11.26M | 11.87M | 9.64M | 7.54M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | +38.39% | -7.18% | +11.04% | |
Gross Income
| 63.54M | 132.69M | 40.88M | 130.12M | |
Gross Income Growth
| - | +108.84% | -69.19% | +218.29% | |
Gross Profit Margin
| +82.04% | +87.33% | +69.59% | +86.77% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 266.33M | 254.11M | 209.13M | 240.70M | |
Research & Development
| 203.32M | 195.16M | 156.94M | 169.65M | |
Other SG&A
| 63.01M | 58.95M | 52.19M | 71.05M | |
SGA Growth
| +18.91% | -4.59% | -17.70% | +15.10% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | (150.93M) | - |
EBIT after Unusual Expense
| (202.79M) | (121.42M) | (17.31M) | (110.58M) | |
Non Operating Income/Expense
| 680.00K | 1.66M | 9.69M | 45.67M | |
Non-Operating Interest Income
| 2.00M | 1.70M | 4.00M | 5.60M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 1.43M | 1.11M | - |
Interest Expense Growth
| - | - | - | -22.03% | - |
Gross Interest Expense
| - | - | 1.43M | 1.11M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (202.12M) | (119.76M) | (9.06M) | (66.02M) | |
Pretax Income Growth
| -55.79% | +40.75% | +92.44% | -628.88% | |
Pretax Margin
| -260.97% | -78.82% | -15.42% | -44.03% | |
Income Tax
| - | - | - | 944.00K | - |
Income Tax - Current - Domestic
| - | - | - | 944.00K | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (202.12M) | (119.76M) | (9.06M) | (66.97M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (202.12M) | (119.76M) | (9.06M) | (66.97M) | |
Net Income Growth
| -55.79% | +40.75% | +92.44% | -639.30% | |
Net Margin Growth
| -260.97% | -78.82% | -15.42% | -44.66% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (202.12M) | (119.76M) | (9.06M) | (66.97M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (202.12M) | (119.76M) | (9.06M) | (66.97M) | |
EPS (Basic)
| -3.3717 | -1.9494 | -0.1463 | -1.0694 | |
EPS (Basic) Growth
| -36.29% | +42.18% | +92.50% | -630.96% | |
Basic Shares Outstanding
| 59.94M | 61.43M | 61.93M | 62.62M | |
EPS (Diluted)
| -3.3717 | -1.9494 | -0.1463 | -1.0694 | |
EPS (Diluted) Growth
| -36.29% | +42.18% | +92.50% | -630.96% | |
Diluted Shares Outstanding
| 59.94M | 61.43M | 61.93M | 62.62M | |
EBITDA
| (191.54M) | (109.55M) | (158.60M) | (103.04M) | |
EBITDA Growth
| -60.82% | +42.80% | -44.77% | +35.03% | |
EBITDA Margin
| -247.31% | -72.10% | -269.96% | -68.71% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 3.40 | |
| Number of Ratings | 7 | Current Quarters Estimate | -0.632 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -1.725 | |
| Last Quarter’s Earnings | -0.399 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.442 | Next Fiscal Year Estimate | -2.54 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 4 | 6 | 2 |
| Mean Estimate | -0.63 | -0.63 | -1.73 | -2.54 |
| High Estimates | -0.57 | -0.56 | -0.02 | -2.18 |
| Low Estimate | -0.72 | -0.74 | -3.01 | -2.90 |
| Coefficient of Variance | -10.73 | -12.55 | -68.75 | -20.04 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 1 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 4 | 4 | 5 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Hold |
SEC Filings for Macrogenics Inc. - MGNX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Macrogenics Inc. - MGNX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 20, 2025 | Eric Risser Chief Operating Officer | 62,422 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Beth Smith VP, Controller & Treasurer | 1,095 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Beth Smith VP, Controller & Treasurer | 9,955 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Jeffrey Peters Senior VP and General Counsel | 13,332 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Jeffrey Peters Senior VP and General Counsel | 13,711 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.56 per share | 35,100.16 |
| Feb 20, 2025 | Jeffrey Peters Senior VP and General Counsel | 18,858 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Stephen L. Eck Chief Medical Officer | 16,665 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Stephen L. Eck Chief Medical Officer | 29,377 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.56 per share | 75,205.12 |
| Feb 20, 2025 | Stephen L. Eck Chief Medical Officer | 34,319 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Eric Risser Chief Operating Officer | 16,665 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Eric Risser Chief Operating Officer | 55,989 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.56 per share | 143,331.84 |
| Feb 20, 2025 | Scott E. Koenig President and CEO; Director | 777,415 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Thomas M. Spitznagel Sr VP, Technical Ops | 13,332 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Thomas M. Spitznagel Sr VP, Technical Ops | 21,402 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.56 per share | 54,789.12 |
| Feb 20, 2025 | Thomas M. Spitznagel Sr VP, Technical Ops | 26,922 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | James Karrels SVP, CFO and Secretary | 14,999 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | James Karrels SVP, CFO and Secretary | 186,801 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.56 per share | 478,210.56 |
| Feb 20, 2025 | James Karrels SVP, CFO and Secretary | 192,591 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Ezio Bonvini Sr VP, Research & CSO | 16,665 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Ezio Bonvini Sr VP, Research & CSO | 124,414 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |